Cwm, LLC Neurocrine Biosciences Inc Transaction History

Cwm, LLC

$25.1 Billion
Q1 2025

A detailed history of Cwm, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Cwm, LLC holds 10,503 shares of NBIX stock, worth $1.31 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,503

Previous 21,887 52.01%

Holding current value

$1.31 Million

Previous $2.99 Million 61.11%

% of portfolio

0.0%

Previous 0.01%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 01, 2025	SELL	$107.22 - $153.29 $1.22 Million - $1.75 Million	-11,384 Reduced 52.01%	10,503 $1.16 Million
Q4 2024 Feb 04, 2025	BUY	$111.62 - $139.44 $1.56 Million - $1.95 Million	14,003 Added 177.61%	21,887 $2.99 Million
Q3 2024 Oct 08, 2024	BUY	$114.58 - $153.15 $118,590 - $158,510	1,035 Added 15.11%	7,884 $908,000
Q2 2024 Jul 09, 2024	BUY	$130.86 - $143.19 $285,929 - $312,870	2,185 Added 46.85%	6,849 $943,000
Q1 2024 Apr 05, 2024	BUY	$130.4 - $143.74 $229,764 - $253,269	1,762 Added 60.72%	4,664 $643,000
Q4 2023 Feb 01, 2024	BUY	$106.07 - $132.76 $90,477 - $113,244	853 Added 41.63%	2,902 $382,000
Q3 2023 Oct 11, 2023	BUY	$94.02 - $117.1 $62,429 - $77,754	664 Added 47.94%	2,049 $231,000
Q2 2023 Aug 03, 2023	BUY	$89.53 - $104.87 $11,370 - $13,318	127 Added 10.1%	1,385 $131,000
Q1 2023 Apr 28, 2023	SELL	$94.11 - $123.02 $3,952 - $5,166	-42 Reduced 3.23%	1,258 $127,000
Q4 2022 Feb 01, 2023	BUY	$106.72 - $127.06 $5,015 - $5,971	47 Added 3.75%	1,300 $155,000
Q3 2022 Oct 27, 2022	BUY	$92.03 - $107.81 $22,547 - $26,413	245 Added 24.31%	1,253 $133,000
Q2 2022 Jul 28, 2022	BUY	$75.79 - $100.07 $35,697 - $47,132	471 Added 87.71%	1,008 $98,000
Q1 2022 Apr 21, 2022	BUY	$72.45 - $94.81 $23,763 - $31,097	328 Added 156.94%	537 $50,000
Q4 2021 Jan 31, 2022	SELL	$79.65 - $106.22 $3,584 - $4,779	-45 Reduced 17.72%	209 $18,000
Q1 2021 Sep 15, 2021	SELL	$87.57 - $119.4 $10,508 - $14,328	-120 Reduced 32.09%	254 $25,000
Q1 2021 Apr 27, 2021	BUY	$87.57 - $119.4 $10,508 - $14,328	120 Added 47.24%	374 $36,000
Q4 2020 Sep 15, 2021	BUY	$86.91 - $108.33 $14,253 - $17,766	164 Added 182.22%	254 $25,000
Q4 2020 Jan 27, 2021	SELL	$86.91 - $108.33 $14,253 - $17,766	-164 Reduced 64.57%	90 $9,000
Q3 2020 Sep 15, 2021	BUY	$96.16 - $135.15 $4,711 - $6,622	49 Added 23.9%	254 $25,000
Q3 2020 Oct 19, 2020	SELL	$96.16 - $135.15 $4,711 - $6,622	-49 Reduced 19.29%	205 $20,000
Q2 2020 Sep 15, 2021	BUY	$85.09 - $130.36 $20,421 - $31,286	240 Added 1714.29%	254 $25,000
Q2 2020 Jul 22, 2020	SELL	$85.09 - $130.36 $20,421 - $31,286	-240 Reduced 94.49%	14 $2,000
Q1 2020 Sep 15, 2021	BUY	$75.11 - $113.76 $17,876 - $27,074	238 Added 1487.5%	254 $25,000
Q1 2020 Apr 28, 2020	SELL	$75.11 - $113.76 $17,876 - $27,074	-238 Reduced 93.7%	16 $1,000
Q4 2019 Sep 14, 2021	BUY	$86.8 - $118.57 $13,454 - $18,378	155 Added 156.57%	254 $25,000
Q4 2019 Jan 27, 2020	SELL	$86.8 - $118.57 $13,454 - $18,378	-155 Reduced 61.02%	99 $11,000
Q3 2019 Sep 14, 2021	BUY	$83.82 - $101.5 $21,290 - $25,781	254 New	254 $25,000
Q3 2019 Oct 22, 2019	SELL	$83.82 - $101.5 $21,290 - $25,781	-254 Closed	0 $0
Q2 2019 Sep 14, 2021	BUY	$72.24 - $91.27 $18,348 - $23,182	254 New	254 $25,000
Q2 2019 Jul 31, 2019	SELL	$72.24 - $91.27 $18,348 - $23,182	-254 Closed	0 $0
Q1 2019 Sep 02, 2021	BUY	$69.31 - $91.53 $16,357 - $21,601	236 Added 1311.11%	254 $0
Q1 2019 Apr 22, 2019	SELL	$69.31 - $91.53 $415 - $549	-6 Reduced 25.0%	18 $2,000
Q4 2018 Jan 25, 2019	BUY	$68.32 - $124.36 $1,639 - $2,984	24 New	24 $2,000

Others Institutions Holding NBIX

# of Institutions

649

Shares Held

97.1M

Call Options Held

749K

Put Options Held

553K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.9B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account